» Articles » PMID: 8407883

Thymidine Phosphorylase Activity Associated with Platelet-derived Endothelial Cell Growth Factor

Overview
Journal J Biochem
Specialty Biochemistry
Date 1993 Jul 1
PMID 8407883
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Partial complementary DNA (cDNA) for thymidine phosphorylase (dThdPase) was cloned by means of a polymerase chain reaction. There was complete sequence identity between the amino acid sequence deduced from the nucleotide sequence of a clone (288 nucleotides) and the residues of platelet-derived endothelial cell growth factor (PD-ECGF). The amino acid sequence of all four peptide fragments from purified human dThdPase could be aligned with that of PD-ECGF. Our data indicate that residues 125-244 of PD-ECGF are identical to the sequence of human dThdPase. The molecular weights of human dThdPase and recombinant PD-ECGF (rPD-ECGF) that lacks 10 amino acids at the amino terminal were 55 and 52 kDa, respectively. Anti-PD-ECGF antibody recognized dThdPase, and anti-dThdPase antibody recognized rPD-ECGF. rPD-ECGF had dThdPase activity and its specific activity was similar to that of purified human dThdPase. dThdPase activity and molecules were detected in COS cells transfected with human PD-ECGF cDNA, but not in nontransfected cells. The sizes of PD-ECGF and dThdPase in the transfected COS cells were identical. These data suggest that human dThdPase is identical to PD-ECGF.

Citing Articles

Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase.

Karamitros C, Somody C, Agnello G, Rowlinson S Front Bioeng Biotechnol. 2022; 9:793985.

PMID: 34976980 PMC: 8718881. DOI: 10.3389/fbioe.2021.793985.


Synthesis of Thymidine Phosphorylase Inhibitor Based on Quinoxaline Derivatives and Their Molecular Docking Study.

Almandil N, Taha M, Farooq R, Alhibshi A, Ibrahim M, Anouar E Molecules. 2019; 24(6).

PMID: 30871147 PMC: 6471342. DOI: 10.3390/molecules24061002.


Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11b/Gr1 myeloid cells.

Iwai T, Harada Y, Saeki H, Oki E, Maehara Y, Yonemitsu Y Oncotarget. 2018; 9(25):17620-17630.

PMID: 29707135 PMC: 5915143. DOI: 10.18632/oncotarget.24811.


The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures.

De Clercq E Med Res Rev. 2009; 31(1):118-60.

PMID: 19844936 PMC: 7168424. DOI: 10.1002/med.20179.


Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.

Lu H, Klein R, Schwartz E Clin Cancer Res. 2009; 15(16):5136-44.

PMID: 19671868 PMC: 2777687. DOI: 10.1158/1078-0432.CCR-08-3203.